Form D · Pharmaceuticals

ARDELYX, INC.

Fremont, CA · CIK 0001437402

Offering snapshot reported Aug 1, 2016 · SEC filing

Reported sold
$110M
Offering amount: $110M
Investors reported
31
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Jul 18, 2016
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 1, 2016Initial$110,000,008No comparison31SEC filing
Jun 22, 2015Initial$77,771,627No comparison11SEC filing
Jul 7, 2011Initial$17,578,665No comparison11SEC filing
Dec 8, 2010Initial$5,013,694No comparison11SEC filing
Jun 9, 2008PaperNot reportedNo comparisonNot reportedSEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-268091

Source: Form D, filed Aug 1, 2016. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Robert Bazemore Director
William Bertrand, Jr. Director
Jeremy Caldwell Executive
Dominique Charmot Director, Executive
David Collier Director
Jean Frechet Director
Elizabeth Grammer Executive
Jeff Jacobs Executive
Annalisa Jenkins Director
Mark Kaufmann Executive
Paul Korner Executive
David Mott Director
Michael Raab Director, Executive
Gordon Ringold Director
Richard Rodgers Director
David Rosenbaum Executive
Peter G. Schultz Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
34175 Ardenwood Blvd. Suite 200
Fremont, CA, 94555